Dual-Action Lenses for Slowing Myopia in Children and Teens: A Randomized, Double-Blind Trial
Key facts
- Who runs it
- Shanghai Eye Disease Prevention and Treatment Center
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 120 people, planned
- Started
- 5 Oct 2026
- Expected to end
- 30 Apr 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dual-Action Myopia-Control Spectacle Lens
- Stellest Myopia-Control Spectacle Lens(Highly Aspherical Lenslet Target / HALT Lens)
- Record updated
- 2 October 2026
Who can take part
- Age
- 6 years to 14 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age 6-14 years
- After cycloplegia with 1% cyclopentolate hydrochloride eye drops (Cyclogyl/Saifeijie), spherical equivalent (SE) of both eyes between -0.50 D and -4.00 D
- Astigmatism of both eyes ≤ 1.50 D; anisometropia ≤ 1.50 D. Best-corrected visual acuity (BCVA) ≥ 5.0
- No use of myopia-control methods within the past 3 months, including defocus lenses, dot diffusion lenses, orthokeratology lenses, defocus soft contact lenses, progressive-addition spectacles, atropine eye drops, red-light therapy, or acupuncture
- Able and willing to wear the study lenses at least 12 hours per day
- Able to attend all scheduled follow-up visits over 12 months (4 follow-up visits after baseline)
- Willing to participate, with written informed consent signed by the legal guardian
Who cannot take part
- Current or past glaucoma, corneal disease, or other organic eye diseases
- Significant systemic disease, psychiatric disorder, or systemic collagen metabolic disease. Diagnosed amblyopia, constant strabismus, or other congenital eye diseases
- Allergy to the materials or products of the study lenses
- Allergy to cycloplegic agents or other ophthalmic examination medications
- Any other condition considered by the investigator to make the participant unsuitable for the study
- Unable to understand the study content or unable to cooperate with follow-up
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 6 and 14 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a single-center, randomized, double-blind, controlled study to test whether a new type of eyeglass lens - a "dual-action" lens that combines two technologies (multiple defocus zones and dot diffusion) - can slow the progression of nearsightedness (myopia) in children and teenagers.
Read full original descriptionShow less
About the participants: Children and adolescents with myopia who meet the study requirements will be randomly assigned (like flipping a coin) to one of two groups. One group will wear the new dual-action lenses, and the other group will wear Stellest lenses, an established myopia-control lens. Neither the participants, their families, nor the eye doctors doing the follow-up exams will know which lens each child is wearing.
About the study: Participants wear their assigned glasses at least 12 hours every day for 12 months and visit the clinic about every 3 months (5 visits in total). At each visit, doctors check eyesight, measure the length of the eyeball, and perform other eye exams. The main goal is to compare how much myopia progresses in the two groups after 12 months, measured by a painless dilated-eye (cycloplegic) refraction test. The study also tracks how comfortable and acceptable the lenses are, and how long children actually wear them each day.
Why this research matters: Myopia in children is increasing worldwide, and effective ways to slow it down are still limited. This study will show whether combining two proven optical technologies in one lens works as well as existing options and is safe and comfortable for daily wear.
The 2 groups in the trial
- Dual-Action LensesTreatment being tested
Treatment: Dual-Action Myopia-Control Spectacle Lens
- Stellest LensesExisting treatment, for comparison
Participants in this arm wear Stellest myopia-control spectacle lenses, an established myopia-control lens with highly aspherical lenslet target (HALT) technology that is already marketed. Participants are instructed to wear the assigned lenses at least 12 hours per day for 12 months. The follow-up schedule and examinations are identical to those in the experimental arm. Neither the participants, their guardians, nor the follow-up examiners know which lens is being worn.
Treatment: Stellest Myopia-Control Spectacle Lens(Highly Aspherical Lenslet Target / HALT Lens)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Controlled Clinical Study of Dual-Action Preventive Lenses for Controlling Myopia Progression in Children and Adolescents
- Criteria questions
- Built from NCT07854457, who can take part
- Record updated
- 2 October 2026